EUROPE UPDATE EXPANSION IN EUROPE
As a result of our commitment and success in all of our already established regions throughout Europe, we are again pleased to announce our continued expansion. Having secured projects in Sweden, Spain and Norway we now have expertise in 8 main land countries demonstrating our long term commitment to our clients. Our expertise in the Data & Pharma sectors and our full understanding of our client’s project needs and requirements allows us to stand out as the preferred contractor. Our core values and successful project delivery without compromise are embedded within each and every member of our team & our trusted supply chain partners.
FEATURE PROJECT- BMS LEIDEN
Errigal Contracts are delighted to have been awarded the full architectural fit out of the Bristol Myers Squibb flagship CAR T cell therapy treatment facility in the Leiden Bio Science Park in the Netherlands. This facility will be fully equipped with the latest technology and production equipment to develop cell therapy for patients in Europe.
Project Key numbers • Contract Value €16.0m • 35 fit-out work packages • 7,500m2 of resin flooring • 1,560m2 of internal glazed screens
• 25,000m2 of wall finishes • 10,000m2 of floor finishes
What is CAR T-Cell Therapy? CAR T-cell therapy is short for 'Chimeric Antigen Receptor T-cell' therapy. A T-cell is an immune cell that can attack and eliminate malignant cancer cells. In the therapy, white blood cells are collected from a cancer patient and genetically modified in the production facility to recognise and bind to proteins from specific cancer cells. These cells are then administered to the patient in specialised centres. The genetic modification of the cells is instrumental in combating haematological cancers through the body's own T-cells. Expanding the capacity of production facilities is essential to make CAR T cell therapy available to more patients with aggressive blood cancers.
Made with FlippingBook Ebook Creator